Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Sola setback spawns new Alzheimer’s work for Lilly
Despite widespread failures biopharma presses on in Alzheimer's, with approaches including BACE and Tau inhibition.
